Concepts (187)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urology | 7 | 2019 | 16 | 2.680 |
Why?
|
| Malpractice | 5 | 2015 | 10 | 1.800 |
Why?
|
| Prostatic Neoplasms | 8 | 2019 | 106 | 1.260 |
Why?
|
| Kidney Neoplasms | 6 | 2018 | 60 | 1.060 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2019 | 178 | 0.910 |
Why?
|
| Clinical Competence | 2 | 2015 | 230 | 0.900 |
Why?
|
| Prostate | 6 | 2019 | 33 | 0.820 |
Why?
|
| Urinary Bladder Neoplasms | 3 | 2012 | 26 | 0.730 |
Why?
|
| Testicular Neoplasms | 4 | 2010 | 22 | 0.720 |
Why?
|
| Ureteral Neoplasms | 1 | 2019 | 3 | 0.710 |
Why?
|
| Vena Cava, Inferior | 1 | 2019 | 10 | 0.710 |
Why?
|
| Carcinoma, Renal Cell | 3 | 2018 | 35 | 0.700 |
Why?
|
| SEER Program | 4 | 2013 | 38 | 0.670 |
Why?
|
| Ureteral Calculi | 1 | 2018 | 2 | 0.670 |
Why?
|
| Ureteroscopy | 1 | 2018 | 2 | 0.670 |
Why?
|
| Kidney Calculi | 1 | 2018 | 4 | 0.670 |
Why?
|
| Simulation Training | 2 | 2019 | 34 | 0.650 |
Why?
|
| Lymph Node Excision | 4 | 2008 | 26 | 0.640 |
Why?
|
| Stents | 1 | 2018 | 76 | 0.640 |
Why?
|
| Nephrectomy | 4 | 2018 | 29 | 0.630 |
Why?
|
| Models, Educational | 1 | 2017 | 36 | 0.620 |
Why?
|
| Internship and Residency | 2 | 2018 | 211 | 0.610 |
Why?
|
| Prostatectomy | 4 | 2012 | 18 | 0.580 |
Why?
|
| Image-Guided Biopsy | 3 | 2019 | 26 | 0.500 |
Why?
|
| Humans | 37 | 2019 | 29337 | 0.470 |
Why?
|
| Male | 28 | 2019 | 15621 | 0.460 |
Why?
|
| Nephrons | 1 | 2012 | 6 | 0.440 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2012 | 13 | 0.430 |
Why?
|
| Neoplasms, Second Primary | 1 | 2012 | 30 | 0.430 |
Why?
|
| Urologic Diseases | 1 | 2011 | 4 | 0.420 |
Why?
|
| Sarcoidosis | 1 | 2011 | 13 | 0.410 |
Why?
|
| Middle Aged | 20 | 2019 | 9823 | 0.410 |
Why?
|
| Marital Status | 1 | 2010 | 15 | 0.390 |
Why?
|
| Insurance, Liability | 1 | 2010 | 1 | 0.390 |
Why?
|
| Postoperative Complications | 6 | 2018 | 957 | 0.360 |
Why?
|
| Penile Neoplasms | 1 | 2008 | 2 | 0.330 |
Why?
|
| Aged | 16 | 2018 | 9448 | 0.320 |
Why?
|
| Adult | 14 | 2018 | 8601 | 0.300 |
Why?
|
| Retrospective Studies | 8 | 2018 | 3273 | 0.300 |
Why?
|
| Ultrasonography | 2 | 2019 | 226 | 0.290 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2004 | 100 | 0.290 |
Why?
|
| Liability, Legal | 1 | 2006 | 7 | 0.290 |
Why?
|
| Biopsy, Needle | 2 | 2005 | 101 | 0.280 |
Why?
|
| Female | 11 | 2019 | 16197 | 0.270 |
Why?
|
| United States | 5 | 2015 | 2333 | 0.260 |
Why?
|
| Pneumothorax | 1 | 2005 | 10 | 0.260 |
Why?
|
| Unnecessary Procedures | 1 | 2005 | 24 | 0.260 |
Why?
|
| Genes, erbB-2 | 1 | 2004 | 6 | 0.250 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2004 | 12 | 0.250 |
Why?
|
| Receptor, ErbB-2 | 1 | 2004 | 41 | 0.240 |
Why?
|
| Vesico-Ureteral Reflux | 1 | 2003 | 7 | 0.230 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2019 | 1221 | 0.230 |
Why?
|
| Multivariate Analysis | 4 | 2013 | 324 | 0.230 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 1 | 2003 | 1 | 0.230 |
Why?
|
| Urinary Bladder | 2 | 2004 | 20 | 0.230 |
Why?
|
| Collagen | 1 | 2003 | 102 | 0.230 |
Why?
|
| Prostatic Hyperplasia | 1 | 2003 | 17 | 0.230 |
Why?
|
| Follow-Up Studies | 7 | 2018 | 1830 | 0.220 |
Why?
|
| Glycoproteins | 1 | 2003 | 58 | 0.220 |
Why?
|
| Rectum | 3 | 2018 | 61 | 0.220 |
Why?
|
| Proportional Hazards Models | 3 | 2013 | 340 | 0.220 |
Why?
|
| Time Factors | 3 | 2017 | 1616 | 0.210 |
Why?
|
| Kidney Transplantation | 1 | 2003 | 125 | 0.200 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2018 | 53 | 0.200 |
Why?
|
| Adenocarcinoma | 1 | 2003 | 189 | 0.200 |
Why?
|
| Treatment Failure | 2 | 2018 | 159 | 0.200 |
Why?
|
| Carcinosarcoma | 1 | 2000 | 4 | 0.190 |
Why?
|
| Kidney Pelvis | 1 | 2000 | 9 | 0.190 |
Why?
|
| Survival Rate | 2 | 2012 | 349 | 0.190 |
Why?
|
| Germinoma | 2 | 1996 | 3 | 0.190 |
Why?
|
| Ultrasonography, Interventional | 2 | 2018 | 63 | 0.170 |
Why?
|
| Neoplasm Invasiveness | 1 | 2019 | 68 | 0.170 |
Why?
|
| Urinary Incontinence, Stress | 1 | 1998 | 3 | 0.170 |
Why?
|
| Fluoroquinolones | 1 | 2018 | 26 | 0.170 |
Why?
|
| Osteomyelitis | 1 | 1998 | 22 | 0.170 |
Why?
|
| Phantoms, Imaging | 1 | 2018 | 42 | 0.170 |
Why?
|
| Surgical Procedures, Operative | 1 | 1998 | 31 | 0.170 |
Why?
|
| Ovariectomy | 1 | 2018 | 26 | 0.170 |
Why?
|
| Ureter | 1 | 2018 | 15 | 0.170 |
Why?
|
| Sickle Cell Trait | 1 | 1998 | 2 | 0.170 |
Why?
|
| Hysterectomy | 1 | 2018 | 19 | 0.170 |
Why?
|
| Preoperative Period | 1 | 2018 | 65 | 0.160 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2017 | 6 | 0.160 |
Why?
|
| Early Detection of Cancer | 1 | 2018 | 79 | 0.160 |
Why?
|
| Renal Veins | 1 | 2017 | 3 | 0.150 |
Why?
|
| Renal Artery | 1 | 2017 | 6 | 0.150 |
Why?
|
| Surgical Stapling | 1 | 2017 | 6 | 0.150 |
Why?
|
| Urinary Catheterization | 1 | 1997 | 6 | 0.150 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2017 | 36 | 0.150 |
Why?
|
| Laparoscopy | 2 | 2017 | 145 | 0.150 |
Why?
|
| Risk Factors | 3 | 2018 | 2443 | 0.150 |
Why?
|
| Amebiasis | 1 | 1996 | 3 | 0.150 |
Why?
|
| Fournier Gangrene | 1 | 1996 | 2 | 0.140 |
Why?
|
| Biomarkers, Tumor | 1 | 1997 | 175 | 0.140 |
Why?
|
| Penile Diseases | 1 | 1996 | 8 | 0.140 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 1996 | 9 | 0.140 |
Why?
|
| Self Report | 1 | 2017 | 218 | 0.140 |
Why?
|
| Postoperative Care | 1 | 1997 | 127 | 0.140 |
Why?
|
| Genital Diseases, Male | 2 | 2011 | 5 | 0.140 |
Why?
|
| Surgical Wound Infection | 1 | 2017 | 97 | 0.140 |
Why?
|
| Attitude of Health Personnel | 1 | 2017 | 148 | 0.140 |
Why?
|
| Incidence | 4 | 2018 | 756 | 0.140 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 1997 | 290 | 0.140 |
Why?
|
| Combined Modality Therapy | 2 | 2012 | 364 | 0.140 |
Why?
|
| Cryosurgery | 1 | 1995 | 20 | 0.140 |
Why?
|
| Penis | 1 | 1996 | 67 | 0.130 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 402 | 0.130 |
Why?
|
| Prostate-Specific Antigen | 2 | 2005 | 16 | 0.120 |
Why?
|
| Prognosis | 3 | 2010 | 840 | 0.120 |
Why?
|
| Penile Induration | 1 | 1996 | 99 | 0.120 |
Why?
|
| Hernia, Inguinal | 1 | 2013 | 16 | 0.120 |
Why?
|
| Aged, 80 and over | 5 | 2018 | 4851 | 0.110 |
Why?
|
| Melanoma | 1 | 2013 | 52 | 0.110 |
Why?
|
| Lung Neoplasms | 1 | 2018 | 625 | 0.110 |
Why?
|
| Neoplasm Staging | 3 | 2018 | 340 | 0.110 |
Why?
|
| Radiotherapy | 1 | 2012 | 50 | 0.110 |
Why?
|
| Kidney | 1 | 2013 | 173 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2018 | 770 | 0.100 |
Why?
|
| Survival Analysis | 1 | 2012 | 298 | 0.100 |
Why?
|
| Pyrimidines | 1 | 2010 | 21 | 0.100 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2010 | 8 | 0.100 |
Why?
|
| Rectal Neoplasms | 1 | 2010 | 19 | 0.100 |
Why?
|
| Kidney Diseases | 1 | 2011 | 115 | 0.090 |
Why?
|
| Treatment Outcome | 4 | 2017 | 3478 | 0.090 |
Why?
|
| Young Adult | 2 | 2017 | 1932 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2010 | 162 | 0.090 |
Why?
|
| Piperazines | 1 | 2010 | 90 | 0.090 |
Why?
|
| Antineoplastic Agents | 1 | 2010 | 218 | 0.080 |
Why?
|
| Adolescent | 4 | 1997 | 2279 | 0.080 |
Why?
|
| Physical Examination | 2 | 2005 | 117 | 0.080 |
Why?
|
| Retroperitoneal Space | 2 | 1997 | 12 | 0.080 |
Why?
|
| Cystectomy | 1 | 2006 | 4 | 0.070 |
Why?
|
| Urination Disorders | 1 | 2005 | 7 | 0.070 |
Why?
|
| Auscultation | 1 | 2005 | 5 | 0.070 |
Why?
|
| Pleura | 1 | 2005 | 9 | 0.070 |
Why?
|
| Respiratory Sounds | 1 | 2005 | 9 | 0.070 |
Why?
|
| Radiography, Thoracic | 1 | 2005 | 28 | 0.070 |
Why?
|
| Case Management | 1 | 2005 | 13 | 0.070 |
Why?
|
| Catheterization, Central Venous | 1 | 2005 | 39 | 0.060 |
Why?
|
| Comorbidity | 2 | 2018 | 498 | 0.060 |
Why?
|
| Intraoperative Complications | 1 | 2005 | 68 | 0.060 |
Why?
|
| Biopsy | 2 | 2018 | 234 | 0.060 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2004 | 29 | 0.060 |
Why?
|
| Gene Amplification | 1 | 2004 | 19 | 0.060 |
Why?
|
| Sensitivity and Specificity | 1 | 2005 | 553 | 0.060 |
Why?
|
| Injections | 1 | 2003 | 56 | 0.060 |
Why?
|
| Androgen Antagonists | 1 | 2003 | 4 | 0.060 |
Why?
|
| Immunohistochemistry | 1 | 2004 | 391 | 0.060 |
Why?
|
| Urinary Tract Infections | 1 | 2003 | 32 | 0.060 |
Why?
|
| Length of Stay | 1 | 2005 | 317 | 0.060 |
Why?
|
| Tissue Donors | 1 | 2003 | 74 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2003 | 260 | 0.050 |
Why?
|
| Diagnosis, Differential | 1 | 2003 | 389 | 0.050 |
Why?
|
| Surveys and Questionnaires | 1 | 2006 | 1184 | 0.050 |
Why?
|
| Lymphatic Metastasis | 2 | 1997 | 81 | 0.050 |
Why?
|
| Neoplasm Proteins | 1 | 2000 | 50 | 0.050 |
Why?
|
| Education | 1 | 2019 | 39 | 0.040 |
Why?
|
| False Positive Reactions | 1 | 2018 | 33 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2018 | 45 | 0.040 |
Why?
|
| Bacterial Infections | 1 | 2018 | 69 | 0.040 |
Why?
|
| Salvage Therapy | 1 | 1997 | 36 | 0.040 |
Why?
|
| Lung | 1 | 2018 | 154 | 0.040 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2017 | 111 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2018 | 394 | 0.040 |
Why?
|
| Arteriovenous Fistula | 1 | 2017 | 9 | 0.040 |
Why?
|
| Ligation | 1 | 2017 | 32 | 0.040 |
Why?
|
| Urethra | 1 | 1997 | 15 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2018 | 288 | 0.040 |
Why?
|
| Ejaculation | 1 | 1996 | 8 | 0.040 |
Why?
|
| Fertility | 1 | 1996 | 20 | 0.040 |
Why?
|
| Spinal Nerve Roots | 1 | 1996 | 29 | 0.040 |
Why?
|
| Mediastinal Neoplasms | 1 | 1996 | 12 | 0.040 |
Why?
|
| Operative Time | 1 | 2017 | 80 | 0.040 |
Why?
|
| Impotence, Vasculogenic | 1 | 1996 | 4 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 333 | 0.030 |
Why?
|
| Patient Discharge | 1 | 1997 | 149 | 0.030 |
Why?
|
| Linear Models | 1 | 2013 | 254 | 0.030 |
Why?
|
| Imatinib Mesylate | 1 | 2010 | 2 | 0.020 |
Why?
|
| Benzamides | 1 | 2010 | 16 | 0.020 |
Why?
|
| Colectomy | 1 | 2010 | 19 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2010 | 53 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2013 | 679 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2005 | 521 | 0.010 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2003 | 17 | 0.010 |
Why?
|
| Age Factors | 1 | 2005 | 843 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2005 | 1811 | 0.010 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2003 | 300 | 0.010 |
Why?
|